2.21

1.56% -0.03

Nuvation Bio Inc (NUVB)

Overview News Price History Option Chain Discussions Forecast

Nuvation Bio Inc stock is traded at $2.21, with a volume of 1.00M. It is down -1.56% in the last 24 hours and down -3.71% over the past month. Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).

Previous Close:

$2.24

Open:

$2.24

24h Volume:

1.00M

Relative Volume:

0.41

Market Cap:

$721.39M

Revenue:

Net Income/Loss:

$-75.80M

P/E Ratio:

-6.3143

EPS:

-0.35

Net Cash Flow:

$-68.07M

1W Performance:

+16.67%

1M Performance:

-3.71%

6M Performance:

-27.70%

1Y Performance:

-8.51%

1-Day Range:

$2.095

$2.29

1-Week Range:

$1.76

$2.42

52-Week Range:

$1.67

$4.1598

Nuvation Bio Inc Stock (NUVB) Company Profile

Name

Nuvation Bio Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(415) 754-3517

Address

357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO

Employee

220

Twitter

Next Earnings Date

2025-03-05

Latest SEC Filings

NUVB's Discussions on Twitter

Compare NUVB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NUVB Nuvation Bio Inc	2.205	721.39M	0	-75.80M	-68.07M	-0.35
VRTX Vertex Pharmaceuticals Inc	501.49	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	682.33	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	578.00	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	241.63	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	250.04	26.76B	3.32B	-860.46M	-1.04B	-8.32

Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-24	Upgrade	Jefferies	Hold → Buy
Mar-26-24	Upgrade	BTIG Research	Neutral → Buy
Jan-06-23	Downgrade	Jefferies	Buy → Hold
Aug-02-22	Downgrade	BMO Capital Markets	Outperform → Market Perform
Aug-02-22	Downgrade	BTIG Research	Buy → Neutral
May-04-22	Initiated	H.C. Wainwright	Buy
Oct-15-21	Resumed	BTIG Research	Buy
Apr-06-21	Initiated	RBC Capital Mkts	Outperform
Mar-08-21	Initiated	BMO Capital Markets	Outperform
Mar-08-21	Initiated	BTIG Research	Buy
Mar-08-21	Initiated	Cowen	Outperform
Mar-08-21	Initiated	Jefferies	Buy
Mar-08-21	Initiated	Wedbush	Outperform

View All

Nuvation Bio Inc Stock (NUVB) Latest News

01:15 AM

Q1 EPS Estimates for Nuvation Bio Decreased by HC Wainwright - Defense World

01:15 AM

Mar 12, 2025

Jones Trading Initiates Coverage of Nuvation Bio (NUVB) with Buy Recommendation - Nasdaq

Mar 12, 2025

Nuvation Bio Positioned for Growth with Key Therapeutics and Strategic Leadership - TipRanks

Mar 12, 2025

Jones Trading sets $10 target for Nuvation Bio stock with Buy rating - Investing.com Australia

Mar 12, 2025

Jones Trading sets $10 target for Nuvation Bio stock with Buy rating By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 11, 2025

Nuvation Bio initiated with a Buy at JonesResearch - TipRanks

Mar 11, 2025

Nuvation Bio (NYSE:NUVB) Shares Gap Down Following Analyst Downgrade - Defense World

Mar 11, 2025

Nuvation Bio (NYSE:NUVB) Price Target Cut to $10.00 by Analysts at HC Wainwright - Defense World

Mar 11, 2025

Nuvation Bio stock price target cut to $10 by H.C. Wainwright - Investing.com Canada

Mar 11, 2025

Mar 10, 2025

Nuvation Bio (NYSE:NUVB) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat

Mar 10, 2025